News 

Mar 8, 2022: The number of "Medical expenses recipients" was updated to FY2020 data in Disease.
Oct 4, 2021: Links to related pediatric diseases were added in Disease.
Sep 28, 2021: DDrare ~ Database of developing drugs, target genes and pathways for rare diseases ~ was added to References.
Jun 11, 2021: Our paper "Drug Target Gene-based Analyses of Drug Repositionability in Rare and Intractable Diseases." was published.
Mar 30, 2021: Data ver. Mar2021. Database system improvement (sort, filter, etc.) and data updates (new info. of age class of patients, etc.) were conducted.
Sep 25, 2020: DDrare - Database of developing drugs, target genes and pathways for rare diseases - was added to References.
Sep 25, 2020: Sitemaps for the three entrances (Disease, Drug and Target Gene/Pathway) were equipped.
Sep 9, 2020: A few drug names were corrected (12,172 drugs -> 12,170 drugs).
Jun 29, 2020: Drugs and target genes shown in Target Gene/Pathway for each disease are now limited to those for the diesase (i.e. Drugs and target genes only for other diseases in a pathway are not shown.). (e.g. Spinal and bulbar muscular atrophy)
Jun 22, 2020: English version has opened.

 About 

DDrare (Database of Drug Development for Rare Diseases) is a database that provides information on drugs in clinical trials, and drug target genes and pathways, related to the intractable diseases (mostly rare diseases) designated by the Ministry of Health, Labour and Welfare (MHLW), Japan.

A list of disease names in English, including synonyms and subclass names, was originally created for the diseases (333 diseases on Mar 2021). Using the list as a query, clinical trials with drug information (DrugBank) was extracted from four major clinical trial registries: JPRN (Japan), ClinicalTrials.gov (US), EU-CTR (Europe), and ChiCTR (China), through WHO-ICTRP website.

Information of drug target genes and pathways (KEGG) is assigned to the extracted drugs. DDrare enables cross-reference of disease, drug, and target gene/pathway information, to be utilized for drug discovery, especially for drug repositioning.

This database was supported by JSPS KAKENHI (20K12056).

- External link
• Intractable diseases designated by the MHLW (in Japanese)    Downloaded in Mar 2021
• Japan Intractable Diseases Information Center (in Japanese)   Referred in Mar 2021
• WHO International Clinical Trials Registry Platform (WHO ICTRP)    Downloaded in Mar 2021
  - Disease names were searched in "Public title", "Scientific title" and "Condition."
  - Recruitment status: ALL
  - Japan Primary Registries Network (JPRN), ClinicalTrials.gov, EU Clinical Trials Register (EU-CTR) and Chinese Clinical Trial Register (ChiCTR), all with drug information in "Intervention."
• DrugBank     Release Version 5.1.8 (The latest on Mar 2021)
  - Name and synonyms were searched in "Intervention."
• KEGG    Downloaded in Mar 2021

 References 

Research Paper

1. Drug Target Gene-based Analyses of Drug Repositionability in Rare and Intractable Diseases. Sci Rep. 2021
2. Trends of Clinical Trials for Drug Development in Rare Diseases. Curr Clin Pharmacol. 2018

Office of Pharmaceutical Industry Research (OPIR) News  Views and Actions (in Japanese)

1. Trends in clinical trials for the designated intractable diseases in Japan - Drug combination - No.57 (Jul 2019)
2. Introducation of DDrare: Database of drug development for the designated intractable diseases in Japan. No.54 (Jul 2018)
3. Trends in clinical trials for the designated intractable diseases in Japan, from the point of view of drug modality. No.53 (Mar 2018)
4. Modality analysis of the drugs used in clinical trials for the designated intractable diseases in Japan. No.52 (Nov 2017)
5. Marketed drugs used in clinical trials for the designated intractable diseases in Japan. No.50 (Mar 2017)
6. Connecting information of the designated intractable diseases in Japan to other databases. No.49 (Nov 2016)
7. Sponsors of clinical trials for the designated intractable diseases. No.49 (Nov 2016)
8. Trends of clinical trials on the designated intractable diseases in Japan. No.48 (Jul 2016)

Symposium of Togo (Integration) (in Japanese)

1. DDrare ~ Database of developing drugs, target genes and pathways for rare diseases ~ 2021
2. DDrare - Database of developing drugs, target genes and pathways for rare diseases - 2020
3. DDrare: Database of drug development for rare diseases providing information of drug target genes and pathways. 2019
4. DDrare: Database of drug development for rare and intractable diseases. 2018
5. Looking for global trends of drug development for rare and intractable diseases by investigating clinical trial data 2017
6. Information analysis for drug development and disease research ~ from basic research to clinical application ~ 2016

 Disclaimer 

The information on this website is provided for research purposes only and does not replace the advice or consultation of a doctor. In principle, all rights relating to the information on this website belong to the National Institutes of Biomedical Innovation, Health and Nutrition. Please contact us in advance if you would like to use the information on this website. Information on this website is subject to change without notice. In any case, we will not be liable for any damages arising from the use of the information on this website.

 Privacy policy 

Handling of personal information on this website

1. The basic policy of the National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN)
   NIBIOHN takes appropriate measures to protect personal information and manage it carefully in accordance with our regulation.
2. Purpose of using personal information
   The registered personal information will be used when the Laboratory of Rare Disease Resource Library, NIBIOHN needs to contact the registrants.
3. Protection of personal information
   The personal information of all registrants is protected based on "Personal Information Management Regulations of NIBIOHN" (Japanese only) and will not be provided to any third parties.
4. Consignment of personal information
   The Laboratory of Rare Disease Resource Library plans to entrust the handling of the personal information of registrants to outsourced companies that have their own regulation for the protection of personal information. If outsourced, the companies shall manage the personal information as carefully as NIBIOHN does.
5. Security of personal information
   The Laboratory of Rare Disease Resource Library will take appropriate and reasonable levels of security management measures for the registered personal information to prevent it from unauthorized access, loss, destruction, falsification and leakage.
6. Personal information consultation office
   National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN)
   Department of General Affairs
   7-6-8, Saito-Asagi, Ibaraki City, Osaka 567-0085, Japan
   Tel:(+81)72-641-9811 Fax:(+81)72-641-9812
   

 Contact us 

Laboratory of Rare Disease Resource Library
Center for Rare Disease Research
National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN)
7-6-8 Saito-Asagi, Ibaraki-shi, Osaka 567-0085, Japan